What Is NAD+?
NAD+ (Nicotinamide Adenine Dinucleotide) is classified as a longevity peptide. NAD+ is a critical coenzyme in every cell, essential for mitochondrial energy production (oxidative phosphorylation), DNA repair via PARP and sirtuin activation, and circadian rhythm regulation. Levels decline ~50% between ages 40-60, contributing to metabolic dysfunction and aging.
It is extensively evaluated in laboratory and clinical settings for its potential to drive cellular energy, dna repair, longevity. Researchers target NAD+ for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Generally well-tolerated. IV NAD+ infusions may cause chest tightness, nausea, and cramping during administration. Subcutaneous injection is better tolerated. Oral precursors (NMN, NR) have good safety profiles in clinical trials.
How Does NAD+ Work?
NAD+ is a critical coenzyme in every cell, essential for mitochondrial energy production (oxidative phosphorylation), DNA repair via PARP and sirtuin activation, and circadian rhythm regulation. Levels decline ~50% between ages 40-60, contributing to metabolic dysfunction and aging.
At the molecular level, NAD+ operates through pathways characteristic of the Longevity class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with cellular energy, dna repair, longevity.
Expected Research Timeline
Weeks 2–4
Improved exercise recovery, better sleep quality, mood stabilization
Months 2–3
Measurable improvements in metabolic markers, sustained energy throughout the day
Long-Term
NAD+ level restoration; potential longevity benefits (animal data for lifespan extension)
What Does the Research Say?
The following are key findings from peer-reviewed studies on NAD+, indexed on PubMed and equivalent databases:
[1]NAD+ decline is a driver of aging
Rajman et al. (Cell Metabolism): Comprehensive review demonstrating NAD+ decline as a hallmark of aging, with restoration improving mitochondrial function, stem cell renewal, and lifespan in animal models.
Evidence: strong[2]NAD+ repletion improves mitochondrial and stem cell function
Zhang et al. (Science): NAD+ supplementation restores mitochondrial function in aged mice, improving muscle stem cell function and extending lifespan.
Evidence: preclinical[3]CD38 dictates age-related NAD decline and mitochondrial dysfunction
Camacho-Pereira et al. (Cell Metabolism): Identifies CD38 as the primary NAD-consuming enzyme that increases with age, explaining the progressive NAD+ decline.
Evidence: preclinical[4]NAD+ intermediates: NMN and NR clinical trial overview
Yoshino et al.: Review of human clinical trials for NAD+ precursors (NMN, NR) showing safe elevation of blood NAD+ levels with improvements in insulin sensitivity and muscle function.
Evidence: moderateSafety & Side Effects
Generally well-tolerated. IV NAD+ infusions may cause chest tightness, nausea, and cramping during administration. Subcutaneous injection is better tolerated. Oral precursors (NMN, NR) have good safety profiles in clinical trials.
| Side Effect | Incidence | Severity |
|---|---|---|
| Nausea during infusion | ~30% (IV route) | moderate |
| Flushing/warmth | ~20% of users | mild |
| Chest tightness | ~15% (IV route) | mild |
| Injection site discomfort | ~10% (SubQ) | mild |
FDA Status: Not Approved for Human Therapeutic Use
NAD+ is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is NAD+ Used?
Route
SubQ
Dose Range
50000–200000 mcg
Frequency
Daily
Cycle
4–12 wk
Timing: Morning
Notes: SubQ: 50-200mg daily. IV: 250-500mg over 2-4 hours. Start low — rapid NAD+ elevation can cause nausea and flushing. Oral precursors (NMN/NR) are an alternative.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
NAD+ vs. Related Compounds
Where to Source NAD+ for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is NAD+?
NAD+ is a longevity peptide. NAD+ is a critical coenzyme in every cell, essential for mitochondrial energy production (oxidative phosphorylation), DNA repair via PARP and sirtuin activation, and circadian rhythm regulation. Levels decline ~50% between ages 40-60, contributing to metabolic dysfunction and aging.
What are the primary research benefits of NAD+?
Published research identifies primary mechanisms targeting: Cellular energy, DNA repair, longevity. These findings come from 4+ peer-reviewed studies indexed in our database.
What is the half-life of NAD+?
In published pharmacokinetic data, NAD+ demonstrates a half-life of approximately 4 hours.
Is NAD+ FDA approved?
NAD+ is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of NAD+?
Reported side effects in published literature include Nausea during infusion (~30% (IV route)), Flushing/warmth (~20% of users), Chest tightness (~15% (IV route)), Injection site discomfort (~10% (SubQ)). Most are classified as moderate in severity.
How is NAD+ administered?
In research settings, NAD+ is typically administered via SubQ. SubQ: 50-200mg daily. IV: 250-500mg over 2-4 hours. Start low — rapid NAD+ elevation can cause nausea and flushing. Oral precursors (NMN/NR) are an alternative.
Sources
- NAD+ decline is a driver of aging. View on PubMed
- NAD+ repletion improves mitochondrial and stem cell function. View on PubMed
- CD38 dictates age-related NAD decline and mitochondrial dysfunction. View on PubMed
- NAD+ intermediates: NMN and NR clinical trial overview. View on PubMed